Life Science Giant Danaher Q3 Earnings: Revenue And EPS Beat, Sticks To Annual Guidance
Portfolio Pulse from Vandana Singh
Danaher Corp (NYSE:DHR) reported strong Q3 earnings, with revenue and EPS beating expectations. The company maintained its annual guidance, highlighting growth in its bioprocessing and molecular testing segments. Despite a slight decline forecasted for 2024, the stock rose 2.18% in premarket trading.
October 22, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Danaher Corp reported Q3 earnings that exceeded expectations, with revenue at $5.79 billion and EPS at $1.71. The company maintained its annual guidance, with positive momentum in bioprocessing and molecular testing. The stock rose 2.18% in premarket trading.
Danaher's Q3 earnings exceeded expectations, with both revenue and EPS beating consensus estimates. The company's reaffirmation of its annual guidance and positive performance in key segments like bioprocessing and molecular testing contributed to a positive market reaction, as evidenced by the 2.18% increase in premarket trading.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100